Life Sciences Workshop: Recent Trends in Pharmaceutical and Biotech Patent Law

Patent practice in the life sciences is constantly evolving. The Federal Circuit has continued to face a plethora of issues that go to the very heart of our patent system, including basic questions such as when subject matter is patentable, what are the presumptions in deciding validity, and even the appropriate standards of review from PTAB and district court proceedings. The PTAB, while initially slow to start with respect to pharmaceutical and biotech proceedings, has gained momentum and there are now a number of significant decisions in this area. And whether you are in a district court litigation or PTAB proceeding, selecting the right expert is vitally important to your success. Please join us as we address these issues and provide insight to help guide your practice.

Topics to be discussed include:

• Patent Cases and Trends to Watch for in 2016

• Changes to the Federal Rules of Civil Procedure

• Update on Biosimilars at the FDA and Federal Courts

• Updates from the Federal Circuit and the USPTO on PTAB Post Grant proceedings

Speakers:
M. Paul Barker
Jonathan R. Davies, Ph.D.
Howard W. Levine
Jeffrey D. Smyth
Jennifer S. Swan

Time:
1:00 – 1:15 p.m.
Registration

1:15 – 4:30 p.m.
Workshop

4:30 – 5:30 p.m.
Reception

Who Should Attend:
General counsel and in-house patent counsel with responsibility for/interest in protecting a company’s intellectual property.

MCLE Credit:
Finnegan confirms that this activity has been certified for 3.0 hours of California MCLE. There is no charge to attend.